SAG
ABVC icon

Spotlight Asset Group’s ABVC BioPharma ABVC Stock Holding History

Spotlight Asset Group’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$77 Hold
100
– – ﹤0.01% 260
2024
Q1 		$131 Hold
100
– – ﹤0.01% 255
2023
Q4 		$104 Hold
100
– – ﹤0.01% 245
2023
Q3 		$104 Hold
100
– – ﹤0.01% 245
2023
Q2 		$520 Buy
+100
New +$665 ﹤0.01% 243

Other funds holding ABVC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Spotlight Asset Group's ABVC Position: Q2 2024 in Review

Spotlight Asset Group held its ABVC BioPharma (ABVC) position steady in Q2 2024 at 100 shares worth $77. The position accounts for ﹤0.01% of the portfolio, ranked #260.

Spotlight Asset Group first reported a position in ABVC in Q2 2023 and has held it in 5 quarters since. The position peaked at $520 in Q2 2023. 11 funds tracked by Wall St. Rank hold ABVC as of Q2 2024.

  • Spotlight Asset Group held 100 shares of ABVC BioPharma worth $77 as of Q2 2024.
  • Spotlight Asset Group left its ABVC BioPharma share count unchanged in Q2 2024.
  • ABVC BioPharma made up ﹤0.01% of Spotlight Asset Group's portfolio in Q2 2024, its #260 holding.
  • Spotlight Asset Group first reported a position in ABVC BioPharma in Q2 2023 and has held it in 5 quarters since.
  • Spotlight Asset Group's ABVC BioPharma position peaked at $520 in Q2 2023.
  • 11 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2024.

Based on Spotlight Asset Group's 13F filing for Q2 2024, filed 24 Jul 2024.